AdAlta and SYNthesis BioVentures partner for innovative immunotherapy development

AdAlta Limited (ASX: $1AD) and SYNthesis BioVentures Fund (SYNBV) have executed a Memorandum of Understanding (MoU) to investigate the formation of a new special purpose entity, AdCella, to provide innovative cellular immunotherapies originating in Asia with a pathway to western regulated markets and enhancement with AdAlta's i-body® technology. The MoU formalizes their commitment to complete due diligence on an extensive in-licensing pipeline of potential near to clinic assets and establish AdCella, combining AdAlta's i-body immunotherapy and clinical capabilities with SYNBV's deep China expertise and access to alternative capital sources.

AdAlta and SYNthesis BioVentures collaboration

SYNBV Managing Director, Prof Andrew Wilks said: 'We are pleased to embark on this collaboration with AdAlta to make AdCella a reality. The opportunity to work with a quality management and clinical team while leveraging our extensive experience in China is an appealing prospect for the SYNthesis Group and for SYNthesis BioVentures in particular. We believe that this collaboration will further our fund's strategy of investing in promising early stage science by leveraging the inherent advantages of the Australian biotech ecosystem.' AdAlta CEO and Managing Director, Tim Oldham said: 'As part of our stated strategy to expand our clinical stage pipeline with assets that work with our i-body® platform, we have identified a unique and exciting opportunity to bring highly innovative cellular immunotherapies to Australian patients. We are delighted to be working with the SYNBV team: their skills, experience and networks in drug development, capital raising and Asia complement ours and significantly strengthens AdCella's competitive position. We will be able to implement this exciting strategy much more rapidly and with greater capital efficiency and reduced risk as a result of this collaboration.'

AdAlta's strategic move and outlook

AdAlta Limited (ASX: $1AD) has partnered with SYNthesis BioVentures Fund (SYNBV) to form AdCella, aiming to bring innovative cellular immunotherapies from Asia to western regulated markets. This strategic move aligns with AdAlta's goal of expanding its clinical stage pipeline and leveraging its i-body® platform. The collaboration with SYNBV, known for its expertise in cross border transactions and access to alternative capital sources, is expected to accelerate the execution of AdAlta's strategy. The company's i-body® technology is well-suited for developing next generation cellular immunotherapies for solid cancers, addressing the challenges of trafficking, targeting, and immune suppression. AdAlta's outlook involves establishing AdCella as a bridge to western regulated markets, providing unique access to Australia's clinical and manufacturing ecosystem, and benefiting Australian patients with earlier access to new therapies. The company's strategy also includes maximizing the products developed using its i-body® platform and entering collaborative partnerships to expand its clinical stage pipeline. AdAlta's ambitions involve securing clinical stage assets that complement the i-body® platform and bringing new hope to patients with cancer through precision engineered, i-body® enabled CAR-T cell therapies.